Intratracheal delivery of aerosolized monoclonal antibodies with specificity for Yersinia pestis LcrV and F1 antigens protected mice in a model of pneumonic plague. These data support the utility of inhaled antibodies as a fast-acting postexposure treatment for plague.
for administration of therapeutics to treat infections caused by inhaled microorganisms (5, 18, 19) . Inhalational delivery of aerosolized antibodies could be used to rapidly generate a high concentration of antibody in the lung milieu, the most likely portal of entry to the body for Y. pestis and other airborne pathogens. Perhaps most importantly, inhaled therapies have the potential for self-administration. In this study we evaluated the therapeutic properties of antibodies administered as an aerosol in a model of pneumonic plague.
All experiments were conducted in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986. Six-to eight-week-old female BALB/c mice (Charles Rivers, Margate, United Kingdom) were exposed to 2,700 CFU aerosolized Y. pestis strain GB as described previously (24) . Strain GB has a minimal lethal dose of approximately 100 CFU following aerosol challenge in our model (17, 23, 24) . Two hours following challenge, mice were anesthetized by intraperitoneal injection of 100 l saline containing 0.6 mg medetomidine (Pfizer, Kent, United Kingdom) and 1.65 mg ketamine (Fort Dodge Animal Heath, Southampton, United Kingdom). A PenCentuary (PenCentuary, Inc., PA) intratracheal microsprayer device was used to deliver MAbs 7.3 and F1-04-A-G1 in a 50-l volume of phosphate-buffered saline (PBS) (3). Protective plague MAbs F1-04-A-G1 (1) and 7.3 (12) were affinity purified from tissue culture cell supernatants as described previously (11) . Each mouse was dosed with 77.5 g of each antibody. Immediately following intratracheal dosing, animals were revived by subcutaneous injection of 0.1 mg atipamezole hydrochloride (Pfizer, Kent, United Kingdom). Mice treated postexposure with MAbs were protected from infection with aerosolized Y. pestis (GB), whereas mice dosed with PBS were not (P Ͻ 0.01; log rank test) (Fig. 1) .
To investigate MAb biodistribution following pulmonary delivery, a cohort of mice were anesthetized and dosed intratracheally with MAb F1-04-A-G1 and MAb 7.3 using the PenCentuary (PenCentuary, Inc., PA) intratracheal microsprayer device as described previously (3) . Mice were dosed with either 15.5 or 77.5 mg of each antibody. Two hours following intratracheal dosing, blood samples were taken by cardiac puncture of terminally anesthetized mice prior to humane killing by cervical dislocation. Blood was stored overnight at 4°C and centrifuged at 12,000 ϫ g, and the serum component was removed by aspiration and stored at Ϫ20°C prior to analysis. Bron-choalveolar lavage wash samples were collected by gently injecting 5 ml of ice-cold lavage medium (0.9% [wt/vol] NaCl, 0.05% [wt/vol] Tween 20, 0.1% [wt/vol] NaN 3 , and 1 mM phenylmethylsulfonyl fluoride) (Sigma, Dorset, United Kingdom) into the trachea to inflate the lungs, by means of an intravenous cannula (Abbott Laboratories, Ireland); antibody solutions were stored at Ϫ20°C prior to analysis. Titration of specific antibody in serum or bronchoalveolar lavage samples was achieved with an indirect enzyme-linked immunosorbent assay as described previously (7) . Anti-LcrV and anti-F1 MAbs were detected in the serum samples of all treated mice ( Table 1 ), indicating that Y. pestis-specific antibodies access the systemic compartment following intratracheal aerosol delivery. There is likely to be significant mucociliary clearance following bronchopulmonary delivery of antibodies (14, 15) . The inability to detect antiLcrV and anti-F1 MAbs in lung wash samples 2 hours after intratracheal administration in all but two of the treated animals is consistent with the thesis that MAbs are either rapidly cleared or absorbed into the blood and lymph (6, 18) .
In summary, these data demonstrate that mice can be protected from aerosol-initiated infection by intratracheal administration of aerosolized Y. pestis-specific antibodies. These data support the development of self-administrable antibody-based drugs for plague treatment, to be used in the event of a bioterrorist attack.
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